grant
Parkinson Disease Clinical Subtypes: Validation, Clinical Utility, and Biological Correlates
Organization WASHINGTON UNIVERSITYLocation SAINT LOUIS, UNITED STATESPosted 1 Apr 2017Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY2026AbbreviationsAbnormal gaitAlzheimer beta-ProteinAlzheimer's Amyloid beta-ProteinAlzheimer's amyloidAmentiaAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid Protein A4Amyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAtrophicAtrophyAutonomic DysfunctionAutopsyAβBehavior assessmentBehavioralBiologicalBiological MarkersBrainBrain Nervous SystemBrain PathologyClassificationClinicalClinical DataClinical assessmentsCognitionCognitiveCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCorpus StriatumCorpus striatum structureDataData SetDegenerative Neurologic DisordersDementiaDepositDepositionDevelopmentDisease ProgressionDisturbance in cognitionDysfunctionDyskinesia SyndromesEconomic BurdenEncephalonEvaluationFamilyFreezingFunctional MRIFunctional Magnetic Resonance ImagingFunctional disorderGaitGait abnormalityGait disorderGait disturbancesGait dysfunctionGait impairmentHallucinationsImpaired cognitionIndividualInterventionLong-term cohortLongitudinal cohortMR ImagingMR TomographyMRIMRIsMT-bound tauMagnetic Resonance ImagingMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedical RecordsMesencephalonMethodsMid-brainMidbrainMidbrain structureMorbidityMotorMovement Disorder SyndromesMovement DisordersNAC precursorNMR ImagingNMR TomographyNerve Transmitter SubstancesNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeurobiologyNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeurotransmittersNuclear Magnetic Resonance ImagingOrthostasisOutcomeOutcome StudyPARK1 proteinPARK4 proteinPETPET ScanPET imagingPETSCANPETTParalysis AgitansParkinsonParkinson DiseaseParticipantPathologyPatient SelectionPatientsPatternPhysiopathologyPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPrimary ParkinsonismProbabilistic ModelsProbability ModelsProteinsRad.-PETResearchSNCASNCA proteinSeverity of illnessSocietiesStatistical ModelsStriate BodyStriatumSubgroupSystemSystematicsTestingTimeTracerTranslatingValidationWalking impairmentZeugmatographya beta peptidea-syna-synucleinabetaalpha synucleinalpha synuclein genealphaSP22amyloid betaamyloid-b proteinasynbehavioral assessmentbeta amyloid fibrilbio-markersbiologicbiologic markerbiomarkercholinergicclinical applicabilityclinical applicationclinical movement disorderclinical relevanceclinical subtypesclinically relevantcognitive dysfunctioncognitive functioncognitive losscohortdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdementia riskdevelopmentaldisease severitydisease subgroupsdisease subtypedisorder subtypefMRIfallsimprovedmicrotubule bound taumicrotubule-bound taumortalitymotor deficitmotor impairmentmovement impairmentmovement limitationmulti-modal neuro-imagingmulti-modalitymultimodal neuroimagingmultimodalitynecropsyneurobiologicalneurodegenerative illnessneuronal NET proteinnon A-beta component of AD amyloidnon A4 component of amyloid precursornon-motor symptomnonmotor symptomnoradrenaline transporternoradrenergicnorepinephrine transporternorepinephrine transporter proteinnovelpathophysiologypatient health informationpatient health recordpatient medical recordpatient stratificationpersonalization of treatmentpersonalized health interventionpersonalized interventionpersonalized medicinepersonalized therapypersonalized treatmentpositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypostmortemprecision interventionspreventpreventingprognostic abilityprognostic powerprognostic utilityprognostic valuepsychiatric symptomrisk factor for dementiarisk for dementiascreeningscreeningsslc6a2 proteinslc6a5 proteinsodium-dependent noradrenaline transportersoluble amyloid precursor proteinsolute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2solute carrier family 6 (neurotransmitter transporter, norepinephrine), member 5statistical linear mixed modelsstatistical linear modelsstratified patientstriataltautau Proteinstau factortoolvalidationsα synuclein geneα-synα-synucleinτ Proteins
Description preview
ABSTRACT
Parkinson disease (PD) is a progressive neurodegenerative disease characterized by motor, cognitive, and
psychiatric manifestations resulting from abnormal protein deposition and neurotransmitter deficits. The
variability in clinical presentation and progression likely reflects different PD subtypes, which may be associated
with the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click